You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion
  1. Xiao-Jie Lu1,
  2. Jing Dong2,
  3. Li-Juan Ji3,
  4. Jin-Hong Luo4,
  5. Huang-Ming Cao4,
  6. Li-Xin Xiao5,
  7. Jun Zhou4,
  8. Chang-Quan Ling6
  1. 1Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
  2. 2Outpatient Department, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China
  3. 3Department of Rehabilitation, The Affiliated Huai'an Hospital of Xuzhou Medical College and The Second People's Hospital of Huai'an, Huai'an, China
  4. 4Department of Oncology and Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
  5. 5Department of Gamma Knife, The 411st Hospital of Chinese People's Liberation Army, Shanghai, China
  6. 6Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai, China
  1. Correspondence to Jun Zhou, Department of Oncology and Hematology, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Rode, Shanghai, 200120, China; zhouyishi1218@163.com; or Chang-Quan Ling, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, 168 Changhai Rode, Shanghai, 200433, China; lingchangquan{at}hotmail.com

https://doi.org/10.1136/gutjnl-2015-310292

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2–3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients’ baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.

    Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has shown favourable effects in treating brain …

    View Full Text

    Footnotes

    • Xiao-Jie Lu, Jing Dong and Li-Juan Ji are co-first authors

    • Contributors JZ and L-XX performed part of the transarterial chemoembolisation and gamma knife surgery procedures. C-QL, JZ and X-JL designed the study. JZ and JD collected the data. J-HL, H-MC and X-JL conducted patient follow-ups. X-JL and L-JJ analysed the data and wrote the manuscript. All authors have read and approved the manuscript.

    • Funding Funded by ‘The 3-Year Promoting Program of Traditional Chinese Medicine by Shanghai Municipal Commission of Health and Family Planning (ZYSNXD-CC-ZDYJ023, ZY3-LCPT-2-1004)’.

    • Competing interests None declared.

    • Ethics approval Institutional Ethics Committee of Changhai Hospital.

    • Provenance and peer review Not commissioned; internally peer-reviewed.